e-ISSN: Pending
Failed Experiment ReportOpen accessMedicine· cited by 22

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)

Per Pfeiffer; Maryam B. Lustberg; Jacques Näsström; Stefan Carlsson; Anders Persson; Fumiko Nagahama; Guido Cavaletti; Bengt Glimelius · 2022 · JNCI Cancer Spectrum

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract

BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR) program aimed to assess efficacy and safety of CaM in the prevention of CIPN in patients treated with oxaliplatin in adjuvant (POLAR-A, ClinicalTrials.gov.NCT04034355) or metastatic (POLAR-M, ClinicalTrials.gov.NCT03654729) settings. METHODS: Two randomized, placebo-controlled phase 3 trials investi

Abstract by Per Pfeiffer; Maryam B. Lustberg; Jacques Näsström; Stefan Carlsson; Anders Persson; Fumiko Nagahama; Guido Cavaletti; Bengt Glimelius, JNCI Cancer Spectrum (2022) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1093/jncics/pkac075